{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:02:26Z","timestamp":1792544546310,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jaad.2020.01.007","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T19:51:18Z","timestamp":1578685878000},"page":"94-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients"],"prefix":"10.1016","volume":"88","author":[{"given":"Ma\u00efa","family":"Delage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Jais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Guet-Revillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Noelle","family":"Ungeheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Henri","family":"Consigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Join-Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.01.007_bib1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.007_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","article-title":"Quality of life impairment in hidradenitis suppurativa. A study of 61 cases","volume":"56","author":"Wolkenstein","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib3","first-page":"827","article-title":"Treatment experience in a local population with hidradenitis suppurativa","volume":"13","author":"Kohorst","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/aje\/kwu078","article-title":"Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States","volume":"179","author":"McMillan","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaad.2020.01.007_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000488344","article-title":"A retrospective cohort study on patients with hidradenitis suppurativa","volume":"234","author":"Seyed Jafari","year":"2018","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2020.01.007_bib6","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/bjd.13866","article-title":"Management of hidradenitis suppurativa: a U.K. survey of current practice","volume":"173","author":"Ingram","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1590\/abd1806-4841.20198607","article-title":"Consensus on the treatment of hidradenitis suppurativa\u2014Brazilian Society of Dermatology","volume":"94","author":"Magalhaes","year":"2019","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib10","series-title":"Dermatologic Surgery: Principles and Practice","first-page":"729","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach","author":"Hurley","year":"1989"},{"key":"10.1016\/j.jaad.2020.01.007_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaad.2009.02.013","article-title":"Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity","volume":"61","author":"Canoui-Poitrine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global VOICE project","volume":"82","author":"Garg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/cid\/cix285","article-title":"The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study","volume":"65","author":"Guet-Revillet","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2020.01.007_bib14","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3201\/eid2012.140064","article-title":"Bacterial pathogens associated with hidradenitis suppurativa, France","volume":"20","author":"Guet-Revillet","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jaad.2020.01.007_bib15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","article-title":"Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa","volume":"222","author":"Join-Lambert","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2020.01.007_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2020.01.007_bib18","first-page":"177","article-title":"[The French version of Skindex (Skindex-France). Adaptation and assessment of psychometric properties]","volume":"130","author":"Leplege","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.007_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0151-9638(07)91613-0","article-title":"[Modifications to the Sartorius score and instructions for evaluating the severity of suppurative hidradenitis]","volume":"134","author":"Revuz","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.007_bib21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Mendonca","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2020.01.007_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"van der Zee","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2020.01.007_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CCID.S136730","article-title":"The effect of oral clindamycin and rifampicin combination therapy in patients with hidradenitis suppurativa in Singapore","volume":"11","author":"Ochi","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib27","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","article-title":"Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations","volume":"80","author":"Caposiena Caro","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients","volume":"28","author":"Bettoli","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.007_bib29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/ced.12933","article-title":"Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up","volume":"41","author":"Dessinioti","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib30","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/bjd.17597","article-title":"Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa?","volume":"180","author":"Caposiena Caro","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ijd.13428","article-title":"Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients","volume":"56","author":"Armyra","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/1471-2334-12-315","article-title":"Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children","volume":"12","author":"Birgy","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jaad.2020.01.007_bib33","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jdv.15597","article-title":"The microbiome of tunnels in hidradenitis suppurativa patients","volume":"33","author":"Ring","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.007_bib34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1592\/phco.20.4.245.34880","article-title":"Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics","volume":"20","author":"Nightingale","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaad.2020.01.007_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1684\/ejd.2013.2213","article-title":"Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination","volume":"24","author":"Join-Lambert","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.007_bib36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jinf.2015.03.013","article-title":"Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination","volume":"71","author":"Bernard","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.jaad.2020.01.007_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jinf.2015.09.015","article-title":"Clindamycin and rifampicin: no bull's eye without a target","volume":"72","author":"Beraud","year":"2016","journal-title":"J Infect"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220300499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220300499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:04:57Z","timestamp":1759273497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220300499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0190962220300499"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.01.007","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}